semaj83/ctmatch_classification huggingface dataset:
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Breast Milk Production First time mothers between the ages of 18 and 45 who have had a vaginal or caesarean delivery and are feeling well First time mothers are used to avoid confounding variables due to previous positive or negative experiences from expressing milk. Their infant will have been born at less than 32.0 weeks of gestation Mothers will intend to breastfeed and are planning to pump milk on site in the NICU at least once/day and will be recruited 7-10 days postpartum Mothers who smoke, are taking medication that may interfere with breastfeeding, and who have undergone prior breast surgery will not be excluded since they are their own control With regard to language, mothers must be able to understand the directions and sign a consent form in English  Mothers will not be recruited whose infant has a low likelihood of survival as determined by the attending physician Mothers who have been diagnosed with mastitis will not be recruited for the study
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Smoking Woman 18-60 Years Old smoking woman 18-60 years old  not smoking Not want to participate in the study
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Contraception Healthy, Mexican female subjects requesting contraception Age >/=18 to </=45 years (inclusive); smokers must not be older than 30 years at the time of informed consent Normal or clinically insignificant cervical smear not requiring further follow-up; a cervical smear has to be taken at the screening visit, or a normal result has to be documented within the previous 6 months. Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASCUS) can be used as an adjunctive test. Subjects with ASCUS can be included if they are negative for high-risk HPV strains  Pregnancy or lactation (less than 6 months since delivery, abortion, or lactation before start of treatment) Body mass index (BMI) >30 kg/m2 Hypersensitivity to any ingredient in the study drug Any diseases or conditions that can compromise the function of body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator Undiagnosed abnormal genital bleeding Abuse of alcohol, drugs or medicine (eg, laxatives) Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 4.0-30.0,  Healthy elective tonsillectomy with or without adenotomy according to clinical indication age >4 and <30 years written informed consent from the study subject or his/her guardian Fluenz® will be used for ages >4 and <30 years, i.e. off-label use of ages >18 and <30 years  systemic anti-inflammatory medication within prior 4 weeks systemic diseases affecting the immune system e.g. autoimmune diseases, immune complex diseases or immune deficiency diseases other than allergy, asthma or atopic dermatitis malignancy, depression, psychiatric illness or medication; planned vaccination during the study period (vaccinations should not be given during study period) forced expiratory volume in 1 second (FEV1) is under 80% of normal value or asthma is in a bad balance for those patients who would participate in the immunotherapy sublingual grass pollen will not be given for children under the age of 5 additional for Grazax® hypersensitivity to any of the excipients (gelatin [fish source], mannitol, sodium hydroxide), inflammatory conditions in the oral cavity with severe symptoms such as oral lichen planus with ulcerations or severe oral mycosis, patients with uncontrolled or severe asthma (in adults: FEV1 < 70% of predicted value after adequate pharmacologic treatment, in children: FEV1 < 80% of predicted value after adequate pharmacologic treatment) addition for Fluenz® hypersensitivity to the active substances, to any of the excipients (sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin [porcine, Type A], arginine hydrochloride, monosodium glutamate monohydrate, gentamicin [a possible trace residue], eggs or to egg proteins [e.g. ovalbumin] and children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Oligomenorrhea Amenorrhea Polycystic Ovary Syndrome (PCOS) Between 18 and 35 years BMI ≥ 18 kg/m2 If ≥ 21 years old, must have had healthy pelvic exam w/in past 2 years Either Regular menstrual cycles (21-35 days) Irregular menstrual cycles (>36 days) with or without a previous diagnosis of PCOS from a primary care provider  Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral contraceptives) or insulin sensitivity Pregnant or breastfeeding Not otherwise healthy
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-48.0,  Polycystic Ovary Syndrome (PCOS) Menstrual Irregularity Between 18 and 48 years BMI ≥ 18 kg/m2 Either Regular menstrual cycles (21-35 days) Irregular menstrual cycles (>36 days); or Previous diagnosis of PCOS from a primary care provider If 21 years of age or older, must have had a healthy pelvic exam w/in the past 2 years  Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral contraceptives) or insulin sensitivity Pregnant or breastfeeding Not otherwise healthy Significant weight changes within the last three months
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Volunteer Healthy male and female volunteers, 18 to 55 years of age inclusive. Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, and a complete physical examination Body mass index (BMI) between 18 to 32 kg/m2 inclusive Nonsmoking subjects and former smoking subjects (who have not smoked for the past six months before first dosing) Female subjects must be surgically sterile or postmenopausal for the past year Male subjects and their partners of childbearing potential must be willing to use two effective methods of contraception, one of which must be a barrier method (e.g., condom) during the study and for 90 days after the last drug administration  Women of childbearing potential, pregnant or lactating women, or males with female partners who are pregnant or lactating Positive urine test for drugs of abuse, alcohol, or cotinine test at screening or prior to admission to the study unit Suspicion of regular consumption of drug(s) of abuse including marijuana Current smokers or subjects who have discontinued smoking less than six months prior to first dosing History (within three months of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption will be prohibited 72 hours prior to entry in the clinical site center and throughout the entire study (including the washout period) until discharge Positive for hepatitis B, hepatitis C, or HIV infection Participation in an investigational drug or device study within 45 days or 5 half-lives (whichever time period is longer) or 6 months for biologic therapies prior to first dosing Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, absorption, distribution, metabolism or excretion of study medication, or that would, in the opinion of the PI, pose an unacceptable risk to the subject in this study History of hypersensitivity to any of the additives in the RO5424802 formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulphate, magnesium stearate) Any history of hypersensitivity to or contraindication to the use of rifampin or other rifamycins or history of severe drug-related allergic reactions or hepatoxicity
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Drug Use History of current or former injection drug use No clinic visits with an HIV provider in the preceding 12 months Not taking ART HIV RNA level of greater than 1,000 copies/mL Agree to attend at least one HIV care visit at the Johns Hopkins Moore clinic  Any medical or psychiatric condition that would interfere with the participant's ability to comply with study procedures or make participation unsafe Current enrollment in another HIV retention-in-care study
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-64.0,  Influenza Provide written informed consent prior to initiation of any study procedures Are able to understand and comply with planned study procedures and be available for all study visits Are males or non-pregnant females, 19 to 64 years old, inclusive Are in good health, as determined by vital signs (oral temperature, pulse, and blood pressure), medical history, and targeted physical examination based on medical history to ensure any existing medical diagnoses or conditions (except those in the Subject  ) are stable . Subjects may be on chronic1 or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity. Note: Topical, nasal, and inhaled medications (with the exception of steroids as outlined in the Subjects (see Section 5.2), vitamins, and contraceptives are permitted Oral temperature is less than 100.4 degrees F Pulse is 50 to 115 bpm, inclusive Systolic blood pressure is 85 to 150 mm Hg, inclusive Diastolic blood pressure is 55 to 95 mmHg, inclusive Erythrocyte sedimentation rate (ESR) is less than 30 mm per hour Alanine aminotransferase (ALT) is less than 44 IU/L for females or is less than 61 IU/L for males Creatinine is less than 1.11 mg/dL for females or is less than 1.38 mg/dL for males White blood cells (WBC) are greater than 3.9 x10^3/UL and less than 10.6 x10^3/UL
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-39.0,  Healthy Women 18-39 years of age who are in good health Good general health as a result of review of medical history and/or clinical testing at the time of screening Available for the duration of the trial Willingness to participate in the study as evidenced by signing the informed consent document Willing to be abstinent or to use non-hormonal methods of contraception for the duration of the study History of normal menstrual cycles (26-35 days in length) for at least 3 months Willingness to refrain from routine vaccination (except as administered during study) for the duration of the study  Use of contraceptive pills, patch, injection or other hormonal therapies in the preceding 3 months (6 months for DepoProvera) A history of hypersensitivity, including anaphylaxis to any of the components of IIV or to eggs Previous receipt of a same season licensed influenza vaccine Pregnancy as determined by a positive urine or serum human choriogonadotropin (β-hCG) test at any point during the study or in the preceding 3 months Currently is lactating or breast-feeding Fewer than 3 normal menstrual cycles since conclusion of last pregnancy or last use of hormonal birth control A history of autoimmune disease, or any other chronic medical condition considered clinically significant by the investigator History of HIV, Hepatitis C or active Hepatitis B Known immunodeficiency syndrome History of Guillain-Barré syndrome
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.333,  Healthy Healthy newborn infant Full term infant (≥ 37 weeks gestation; ≤ 42 weeks gestation) Age of infant is between 14 days at the time of enrollment Birth weight between 2500g and 4500g For the Formula fed groups: The infant's mother has elected, before the 14th day of their child's life, not to continue breastfeeding (no breastfeeding after the 14th day of the child's life) For the Breastfed group: The infant's mother has elected to fully breastfeed her baby, from enrollment to at least 3 months of age Having obtained his/her legal representative's informed consent  Congenital illness or malformation that may affect normal growth Significant pre-natal and/or post-natal disease Re-hospitalization for more than 2 days in the first 14 days of life. (Exceptionally, infants re-hospitalized because of jaundice may be enrolled in the study) Newborn who have received antibiotics during the first 14 days of life Receiving infant formula containing pro and/or prebiotics at the time of enrolment Newborn whose parents / caregivers cannot be expected to comply with treatment Newborn currently participating in another clinical trial
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Adult Lymphoblastic Lymphoma Disease ALL in complete remission (CR) at the time of transplant. Remission is defined as "less than 5.0% bone marrow lymphoblasts by morphology," as determined by a bone marrow aspirate obtained within 2 weeks of study registration Philadelphia chromosome positive ALL is allowed Lymphoid blastic crisis of CML will be included (provided that patients achieve CR) Age Equal or above age 40 and up to 65 years. If younger than 40, there must be comorbidities which preclude the patient to undergo CyTBI conditioning regimen Organ Function All organ function testing should be done within 28 days of study registration Cardiac: Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA (Multi Gated Acquisition) scan or echocardiogram Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital capacity) ≥ 50% predicted, DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) ≥ 50% of predicted Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60 mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula: CrCl = (140-age) x weight (kg) x 0.85 (if female)/72 x serum creatinine (mg/dL) Hepatic  Non-compliant to medications No appropriate caregivers identified HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive Active life-threatening cancer requiring treatment other than ALL Uncontrolled medical or psychiatric disorders Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest CT scan within 14 days of registration Active central nervous system (CNS) leukemia Preceding allogeneic HSCT Receiving intensive chemotherapy within 21 days of registration. Maintenance type of chemotherapy will be allowed